Share-based Payment Arrangement, Expense of Outlook Therapeutics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Outlook Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Outlook Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,812,999, a 29% increase year-over-year.
  • Outlook Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,859,896, a 65% increase year-over-year.
  • Outlook Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $8,859,896, a 65% increase from 2024.
  • Outlook Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,385,124, a 2.9% decline from 2023.
  • Outlook Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,547,019, a 28% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Outlook Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,859,896 $1,812,999 +$407,302 +29% 01 Jul 2025 30 Sep 2025 10-K 19 Dec 2025 2025 FY
Q2 2025 $8,452,594 $1,670,812 +$274,503 +20% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q3
Q1 2025 $8,178,091 $1,703,665 +$393,158 +30% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q2
Q4 2024 $7,784,933 $3,672,420 +$2,399,809 +189% 01 Oct 2024 31 Dec 2024 10-Q 14 Feb 2025 2025 Q1
Q3 2024 $5,385,124 $1,405,697 +$16,281 +1.2% 01 Jul 2024 30 Sep 2024 10-K 19 Dec 2025 2025 FY
Q2 2024 $5,368,843 $1,396,309 +$14,504 +1% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q3
Q1 2024 $5,354,339 $1,310,507 -$72,898 -5.3% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q2
Q4 2023 $5,427,237 $1,272,611 -$119,782 -8.6% 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025 2025 Q1
Q3 2023 $5,547,019 $1,389,416 +$13,329 +0.97% 01 Jul 2023 30 Sep 2023 10-K 27 Dec 2024 2024 FY
Q2 2023 $5,533,690 $1,381,805 +$13,931 +1% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q3
Q1 2023 $5,519,759 $1,383,405 -$2,379,390 -63% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q2
Q4 2022 $7,899,149 $1,392,393 +$188,345 +16% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q1
Q3 2022 $7,710,804 $1,376,087 -$28,428 -2% 01 Jul 2022 30 Sep 2022 10-K 22 Dec 2023 2023 FY
Q2 2022 $7,739,232 $1,367,874 +$169,490 +14% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q3
Q1 2022 $7,569,742 $3,762,795 +$2,633,048 +233% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q2
Q4 2021 $4,936,694 $1,204,048 +$49,407 +4.3% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023 2023 Q1
Q3 2021 $4,887,287 $1,404,515 +$619,822 +79% 01 Jul 2021 30 Sep 2021 10-K 29 Dec 2022 2022 FY
Q2 2021 $4,267,465 $1,198,384 -$160,336 -12% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q3
Q1 2021 $4,427,801 $1,129,747 +$825,208 +271% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q2
Q4 2020 $3,602,593 $1,154,641 +$795,164 +221% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2022 Q1
Q3 2020 $2,807,429 $784,693 +$580,124 +284% 01 Jul 2020 30 Sep 2020 10-K 23 Dec 2021 2021 FY
Q2 2020 $2,227,305 $1,358,720 +$1,389,985 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q3
Q1 2020 $837,320 $304,539 +$36,797 +14% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q2
Q4 2019 $800,523 $359,477 -$512,812 -59% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q1
Q3 2019 $1,313,335 $204,569 01 Jul 2019 30 Sep 2019 10-K 23 Dec 2020 2020 FY
Q2 2019 $31,265 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q3
Q1 2019 $267,742 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q2
Q4 2018 $872,289 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2020 2020 Q1

Outlook Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $8,859,896 +$3,474,772 +65% 01 Oct 2024 30 Sep 2025 10-K 19 Dec 2025 2025 FY
2024 $5,385,124 -$161,895 -2.9% 01 Oct 2023 30 Sep 2024 10-K 19 Dec 2025 2025 FY
2023 $5,547,019 -$2,163,785 -28% 01 Oct 2022 30 Sep 2023 10-K 27 Dec 2024 2024 FY
2022 $7,710,804 +$2,823,517 +58% 01 Oct 2021 30 Sep 2022 10-K 22 Dec 2023 2023 FY
2021 $4,887,287 +$2,079,858 +74% 01 Oct 2020 30 Sep 2021 10-K 29 Dec 2022 2022 FY
2020 $2,807,429 +$1,494,094 +114% 01 Oct 2019 30 Sep 2020 10-K 23 Dec 2021 2021 FY
2019 $1,313,335 01 Oct 2018 30 Sep 2019 10-K 23 Dec 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.